Search Results - "İbrahim C. Haznedaroğlu"

The effects of blood group types on the risk of COVID-19 infection and its clinical outcome by Göker, Hakan, Aladağ Karakulak, Elifcan, Demiroğlu, Haluk, Ayaz Ceylan, Çağlayan Merve, Büyükaşik, Yahya, Inkaya, Ahmet Çağkan, Aksu, Salih, Sayinalp, Nilgün, Haznedaroğlu, Ibrahim Celalettin, Uzun, Ömrüm, Akova, Murat, Özcebe, Osman Ilhami, Ünal, Serhat

“…COVID-19 (Coronavirus disease of 2019) is an infectious disease outbreak later on declared as a pandemic, caused by the SARS-CoV-2 (severe acute respiratory…”
Get full text

Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia by Tokatlı, Mert, Ismayilov, Rashad, Erkin Çınar, Olgu, Haznedaroğlu, İbrahim C.

Get full text

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors by Haznedaroğlu, İbrahim C., Kuzu, Işınsu, İlhan, Osman

“…Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be manageable with tyrosine…”
Get full text

Branch retinal vein occlusion associated with platelet activation by BEYAZYILDIZ, Emrullah, ÇITIRIK, Mehmet, ŞIMŞEK, Mert, BEYAZYILDIZ, Özlem, C. HAZNEDAROĞLU, İbrahim

Get full text

COVID-19, Renin-Angiotensin System, and Hematopoiesis by Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.

“…We had initially indicated that there is a local hematopoietic bone marrow (BM) renin-angiotensin system (RAS), active in the physiological and pathological…”
Get full text

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases by Koluman, Ahmet, Akar, Nejat, Haznedaroğlu, İbrahim C

“…Ankaferd hemostat (Ankaferd Blood Stopper®, ABS)-induced pharmacological modulation of essential erythroid proteins can cause vital erythroid aggregation via…”
Get full text

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to their Plasmacytoma Presentation at Diagnosis by Çiftçiler, Rafiye, Göker, Hakan, Demiroğlu, Haluk, Aksu, Salih, Sayınalp, Nilgun, Haznedaroğlu, İbrahim C., Malkan, Ümit Yavuz, Büyükaşık, Yahya, Özcebe, Osman

“…Multiple myeloma (MM) associated with extramedullary (EM) plasmacytoma has a poor therapeutic response and poor outcomes when treated with conventional…”
Get full text

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug by Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.

“…We have read with great interest the paper by Patıroğlu et al. [1] on the mucosal healing effects of Ankaferd BloodStopper (ABS), recently published in this…”
Get full text

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia by Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C., Sayınalp, Nilgün, Özcebe, Osman, Aksu, Salih, Demiroğlu, Haluk, Göker, Hakan, Malkan, Ümit Yavuz, Büyükaşık, Yahya

“…The prognosis of patients with acute myeloid leukemia (AML) is affected by factors that are both patient- and disease-specific. The aim of this study is to…”
Get full text

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia by Okay, Müfide, Çetik, Sıla, Haznedaroğlu, İbrahim C.

“…Targeting hepatic tumors through locoregional application is feasible for anti-tumoral management [1]. Transarterial chemoembolization (TACE) aims to localize…”
Get full text

Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study by Canbaz, Hayri, İdiz, Ufuk Oğuz, Cankar Dal, Hayriye, Kaçıroğlu, Fatih, Taş, Seher, Çubukçu, Hikmet Can, Beştemir, Attila, Gülşen, Murat, Polat, İstemi Taha, Laloğlu, Abubekir, Tör, İbrahim Hakkı, Akkurt, Halik Ekrem, Ateş, Utku, Reisli, İsmail, Koç, Esin, İnkaya, Ahmet Çağkan, Karakükçü, Musa, Ceylan, Mustafa, Haznedaroğlu, İbrahim Celalettin, Akın, Haluk

“…Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are…”
Get full text

Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey by Soyer, Nur, Ali, Rıdvan, Turgut, Mehmet, Haznedaroğlu, İbrahim Celalettin, Yılmaz, Fergün, Aydoğdu, İsmet, Pir, Ali, Karakuş, Volkan, Özgür, Gökhan, Kiş, Cem, Ceran, Funda, İlhan, Gül, Özkan, Melda, Aslaner, Müzeyyen, İnce, İdris, Yavaşoğlu, İrfan, Gediz, Füsun, Sönmez, Mehmet, Güvenç, Birol, Özet, Gülsüm, Kaya, Emin, Vural, Filiz, Şahin, Fahri, Töbü, Mahmut, Durusoy, Raika, Saydam, Güray

“…The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. From 15 centers, 176 patients (53.4% male, 46.6%…”
Get full text

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms by Soyer, Nur, Haznedaroğlu, İbrahim C, Cömert, Melda, Çekdemir, Demet, Yılmaz, Mehmet, Ünal, Ali, Çağlıyan, Gülsüm, Bilgir, Oktay, İlhan, Osman, Özdemirkıran, Füsun, Kaya, Emin, Şahin, Fahri, Vural, Filiz, Saydam, Güray

“…Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are…”
Get full text

Splenic artery embolization with Ankaferd blood stopper in a sheep model by Koç, Osman, Acar, Kadir, Özbek, Orhan, Güler, İbrahim, Sarıtaş, Kadir, Erdem, Tuba Bera, Solak, Yalçın, Toy, Hatice, Küçükapan, Ahmet, Özbek, Seda, Gaipov, Abduzhappar, Haznedaroğlu, İbrahim C

“…Splenic artery embolization is a minimally invasive therapeutic procedure utilized in a number of disorders. Ankaferd blood stopper (ABS) is a novel hemostatic…”
Get full text

Pathological haemostasis and ‘prothrombotic state’ in Behçet's disease by Kiraz, Sedat, Ertenli, İhsan, Öztürk, M.Akif, Haznedaroğlu, İbrahim C., Çelik, İsmail, Çalgüneri, Meral

“…Behçet's disease (BD) is a widespread occlusive-type vasculitis with life-threatening manifestations. The vasculopathy of BD is unique and any type of vessel…”
Get full text

The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice by Malkan, Ümit Yavuz, Güneş, Gürsel, Göker, Hakan, Haznedaroğlu, İbrahim C, Acar, Kadir, Eliaçık, Eylem, Etgül, Sezgin, Aslan, Tuncay, Balaban, Seda, Demiroğlu, Haluk, Özcebe, Osman I, Sayınalp, Nilgün, Aksu, Salih, Büyükaşık, Yahya

“…Many studies reported an improved prognosis in patients with Burkitt's lymphoma obviating the need of stem cell transplantation. However, prognosis of the…”
Get full text

The impact of eltrombopag administration on the clinical course of severe refractory fatal acquired aplastic anemia by Işık, Ayşe, Eliaçık, Eylem, Haznedaroğlu, Ibrahim C, Aksu, Salih, Sayınalp, Nilgün, Büyükaşık, Yahya, Göker, Hakan, Ozcebe, Osman

Get full text

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma by Ghasemi, Mehdi, Alpsoy, Semih, Türk, Seyhan, Malkan, Ümit Y, Atakan, Şükrü, Haznedaroğlu, İbrahim C, Güneş, Gürsel, Gündüz, Mehmet, Yılmaz, Burak, Etgül, Sezgin, Aydın, Seda, Aslan, Tuncay, Sayınalp, Nilgün, Aksu, Salih, Demiroğlu, Haluk, Özcebe, Osman I, Büyükaşık, Yahya, Göker, Hakan

“…Multiple myeloma (MM) is currently incurable due to refractory disease relapse even under novel anti-myeloma treatment. In silico studies are effective for key…”
Get full text

Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature by Uz, Burak, Eliaçık, Eylem, Işık, Ayse, Aksu, Salih, Büyükaşık, Yahya, Haznedaroğlu, Ibrahim C, Göker, Hakan, Sayınalp, Nilgün, Ozcebe, Osman İ

“…Additional chromosomal abnormalities in acute myelogenous leukemia have been identified as one of the most important prognostic factors. Favorable chromosomal…”
Get full text

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms by Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman I, Haznedaroğlu, İbrahim C

“…Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with…”
Get full text